Novo Nordisk NVO has seen strong momentum in recent years, driven by the commercial success of its blockbuster semaglutide products, Wegovy (obesity) and Ozempic (diabetes). Building upon this ...

June 6 (Reuters) - Novo Nordisk's (NOVOb.CO), opens new tab popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition that can lead to vision ...

European regulators have confirmed that Novo Nordisk’s semaglutide increases the risk of a rare eye condition that can cause vision loss. The conclusion from the European Medicines Agency (EMA) ...

The timing felt right — 2025 marked the 60th anniversary of the founding of Balkanske Igre, the Balkan dance group that runs the festival. That group, an offshoot of another student folk dancing ...

Novo Nordisk is locked in a patent infringement battle with Dr Reddy’s Laboratories and OneSource Specialty Pharma. SENSEX 82,408.17 + 1,046.30. NIFTY 25,112.40 + 319. ...

Also Read: OneSource bets on weight loss drugs to reach 2028 revenue goal The court’s intervention comes at a crucial time as Novo Nordisk gears up for the rollout of Wegovy, amid rising global demand ...

A legal tangle hovers over Novo Nordisk’s diabetes and weightloss drug semaglutide, just weeks ahead of the possible launch of its injectible version Wegovy in India. Semaglutide is the active ...

Novo Nordisk has filed a lawsuit in Delhi High Court. The suit aims to stop Dr Reddy's Laboratories and OneSource from selling semaglutide in India. Semaglutide is the active ingredient in Wegovy. The ...